Form 4 for EW Edwards Lifesciences
Accepted 2025-12-12 00:00:00 ET · period of report 2025-12-12 · accession 0001225208-25-009934 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-12-12 | 2025-12-12 | EW | Lippis Daniel J. | CVP, JAPAC | M - OptEx | $59.26 | +1,019 | 23.0K | +5% | +$60.4K |
| D | 2025-12-12 | 2025-12-12 | EW | Lippis Daniel J. | CVP, JAPAC | S - Sale+OE | $84.03 | -1,019 | 22.0K | -4% | -$85.6K |
| D | 2025-12-12 | 2025-12-12 | EW | Lippis Daniel J. | CVP, JAPAC | M - OptEx | $0.00 | -1,019 | 5,095 | -17% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-12 | M | A | 1,019 | $59.26 | 23,020.91 | D | — | — | |
| 2 | Common | Common Stock | 2025-12-12 | S | D | 1,019 | $84.03 | 22,001.91 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $83.58 to $84.46. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
| 3 | Derivative | Employee Stock Option (Right to Acquire) | 2025-12-12 | M | D | 1,019 | $0.00 | 5,095 | D | $59.26 · 2020-05-08 to 2026-05-07 | 1,019 Common Stock |